What Oncology Drug Developers Should Expect from the FDA’s Project Optimus
11:29
Predicting and Taming Immunogenicity: Overview of Immunogenicity & ADA Assays
59:00
What is FDA Project Optimus and How Will it Impact Oncology Drug Development?
42:27
What you should know about FDA Project Optimus for your oncology drug approval
43:39
MERIT Webinar: RECIST 1.1 & Oncology Trial Endpoints
54:15
PBPK modeling of Distinct Change in OATP1B Substrate Pharmacokinetics during OATP1B-Mediated DDIs
27:03
Antibody Drug Conjugates: The end of chemotherapy | 2023 West Oncology Conference
1:28:43
Modeling and Simulation to Select Oncology Dosages - Session 1
47:08